文献速递消化系统肿瘤胸部肿瘤乳腺癌

结直肠癌、肺癌和乳腺癌老年幸存者阿片类药物使用趋势

Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers.
PubMed 文献 · J Clin Oncol · 2019-02-28

利用SEER与Medicare数据,比较2008至2013年诊断的结直肠癌、肺癌和乳腺癌老年幸存者与匹配非癌对照的慢性阿片类药物使用情况。结果显示,诊断后第一年结直肠癌和肺癌幸存者的慢性使用高于对照,乳腺癌幸存者低于对照,差异逐年缩小,至诊断后6年幸存者不再更可能成为慢性使用者。

要点

  • 诊断后第一年,结直肠癌幸存者慢性阿片类药物使用高于对照(OR 1.34,95%CI 1.22-1.47)。
  • 诊断后第一年,肺癌幸存者慢性阿片类药物使用高于对照(OR 2.55,95%CI 2.34-2.77)。
  • 乳腺癌幸存者诊断后每年慢性阿片类药物使用均低于对照。

核心结论

  • 在三个大型老年癌症幸存者人群中,慢性阿片类药物使用因癌症类型而异,但诊断后6年幸存者不再比对照更可能成为慢性使用者。

研究设计与样本

  • 利用SEER和Medicare数据进行的多水平logistic回归分析,纳入2008至2013年诊断的结直肠癌、肺癌和乳腺癌老年幸存者及匹配非癌对照。
  • 共纳入46,789例幸存者和138,136例非癌对照。

主要发现

  • 诊断后第一年,结直肠癌幸存者慢性阿片类药物使用高于对照(OR 1.34,95%CI 1.22-1.47)。
  • 诊断后第一年,肺癌幸存者慢性阿片类药物使用高于对照(OR 2.55,95%CI 2.34-2.77)。
  • 诊断后每年,幸存者与对照间慢性使用差异逐渐缩小。
  • 诊断后每年,乳腺癌幸存者慢性使用均低于对照。
  • 在诊断后前3至5年,慢性使用的幸存者比慢性使用的对照更可能使用高日剂量。

关键数值与推荐

  • 慢性阿片类药物使用定义为连续使用≥90天。
  • 高剂量阿片类药物使用定义为平均每日≥90吗啡毫克当量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cancer survivors may be at increased risk for opioid-related harms. Trends in opioid use over time since diagnosis are unknown. METHODS: Using data from SEER and Medicare, we conducted multilevel logistic regression analyses to compare chronic opioid use (≥ 90 consecutive days) among opioid-naïve survivors of colorectal, lung, and breast cancers diagnosed from 2008 to 2013 and matched with noncancer controls. Among cases and controls with chronic use, we compared rates of high-dose opioid use (average ≥ 90 morphine milligram equivalents daily). RESULTS: We included 46,789 survivors and 138,136 noncancer controls. In the first year after the index date (survivor's diagnosis date), chronic use among colorectal and lung cancer survivors exceeded chronic use among controls (colorectal cancer: odds ratio, 1.34; 95% CI, 1.22 to 1.47; lung cancer: odds ratio, 2.55; 95% CI, 2.34 to 2.77). Differences in chronic use between survivors and controls declined each year after the index date. Chronic use among breast cancer survivors was less than that of controls each year after the index date. Survivors with chronic use were more likely to have a high daily dose than controls with chronic use in the first 3 to 5 years. CONCLUSION: Among three large populations of older cancer survivors, chronic opioid use varied by cancer. However, by 6 years after diagnosis, survivors were no longer more likely to be chronic users than controls. Strategies for appropriate pain management during and after cancer treatment should take into account the risks associated with chronic high-dose opioid use.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Salz T, Lavery JA, Lipitz-Snyderman AN, et al. Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers. J Clin Oncol. 2019. PMID: 30817249. doi:10.1200/JCO.18.00938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。